crizotinib + ipilimumab

Crizotinib + ipilimumab is an investigational combination therapy consisting of two distinct agents used in oncology. Crizotinib is a small molecule tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK), ROS1, and MET tyrosine kinases. It is primarily indicated for ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC) and other ALK-driven malignancies. Ipilimumab is a monoclonal antibody that acts as an immune checkpoint inhibitor by targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), thereby enhancing T-cell mediated anti-tumor responses. The combination has been studied in early-phase clinical trials for patients with advanced NSCLC harboring EGFR mutations or ALK rearrangements to assess safety and preliminary efficacy. Early results indicate notable progression-free survival but also significant toxicity concerns[2][6].

Other names

crizotinibum(R)-crizotinibPF 2341066PF2341066PF-2341066